Format

Send to

Choose Destination
Curr Opin Pediatr. 2016 Feb;28(1):26-33. doi: 10.1097/MOP.0000000000000298.

Future directions in the treatment of osteosarcoma.

Author information

1
aDepartment of Oncology, St. Jude Children's Research Hospital bDepartment of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee cDana-Farber Cancer Institute, Boston, Massachusetts dDivision of Pediatric Hematology/Oncology, The Children's Hospital At Montefiore, Bronx, New York, USA.

Abstract

PURPOSE OF REVIEW:

Overall survival rates for osteosarcoma have remained essentially unchanged over the past 3 decades despite attempts to improve outcome via dose intensification and modification based on response. This review describes recent findings from contemporary clinical trials, advances in the comprehension of osteosarcoma biology and genomic complexity, and potential opportunities using targeted and immune-mediated therapies.

RECENT FINDINGS:

Recent results from international collaborative trials have failed to demonstrate an ability to improve outcomes using a design in which the randomized question is dictated based on histologic response to preoperative chemotherapy. Novel prognostic markers assessable at diagnosis are vital to identifying subsets of osteosarcoma. Clinical trials focus has now shifted to serial phase II studies of novel agents to evaluate for activity in recurrent and refractory disease. In-depth analyses have revealed profound genomic instability and heterogeneity across patients, with nearly universal TP53 aberration. Although driver mutational events have not clearly been established, frequent derangements in specific pathways may suggest opportunities for therapeutic exploitation. Genomic complexity may lend support to a role for immune-mediated therapies.

SUMMARY:

Rigorous preclinical investigations are potentially generating novel strategies for the treatment of osteosarcoma that will inform the next generation of clinical trials, with the opportunity to identify agents that will improve survival outcomes.

PMID:
26626558
PMCID:
PMC4761449
DOI:
10.1097/MOP.0000000000000298
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center